Somite is building the OpenAI of cellular biology. Their initial focus is to build AI foundation models to produce human tissue for cell therapies. With their proprietary “digital twins of the embryo” and differentiation protocols, Somite addresses current cell therapy limitations - illusive cell lineages, purity, scale, and cost, with ML-guided models to make cell replacement therapies a reality.

‍

Somite is leveraging over 12 years of work at HMS, has compelling pre-clinical data, and owns the seminal patents in the space. To date, they are the only company to efficiently produce human somite-derived cells in vitro. Somite has the potential to cure a wide range of diseases that involve the loss or deficiency of cell populations, such as Diabetes, Obesity, and Muscular Dystrophies.‍

‍

www.somite.ai

‍